Navigation Links
Creabilis Raises €15M ($20M) in Series B Fundraising Round
Date:10/4/2011

ster@creabilis-sa.com
Creabilis SA
5 rue Jean Monnet L-2810 LUXEMBOURG
                   
Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44(0)20-7282-1050
E-mail: nina.enegren@citigatedr.co.uk

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.

Creabilis' lead product is CT327 a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis and is undergoing proof-of-concept studies in pain. CT340 is a potent TrkA kinase inhibitor under development for the treatment of conditions in which TrkA kinase inhibition is indicated, including inflammatory arthritis, and pain. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions, such as rheumatoid arthritis. Earlier-stage projects include a number of highly promising candidates for dermatological and wider indications.

Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners, Neomed and Abbott Biotech Ventures.

For more information, please visit:  http://www.creabilis-sa.com



'/>"/>
SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Creabilis Appoints Dr David Roblin as Chief Medical Officer
2. Creabilis Expands Senior Management Team
3. Bacon Eating Contest Raises Money for American Heart Association
4. Proteolix Raises $79 Million in Series C Financing
5. Yongye Biotechnology International Raises $9.4 Million in Private Placement
6. MacroGenics Raises $25M in Series D-2 Financing
7. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
8. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
9. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
10. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
11. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... 23, 2014  Sofinnova Ventures, a Menlo ... closing of Sofinnova Venture Partners IX, L.P. at the ... the initial fund target of $425 million. ... companies. Consistent with recent funds, SVP IX will provide ... programs, along with select investments in earlier stage opportunities. ...
(Date:7/23/2014)... 23, 2014 OncLive® is pleased ... has joined its Strategic Alliance Partnership program. ... program, UNC Lineberger will have the opportunity to ... of its cutting-edge research initiatives, community-directed cancer prevention ... will work with OncLive to educate their peers ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Sinobiopharma Pharmaceutical Group (OTC Bulletin Board: SNBP) is ... Tan as Director of Marketing.Ms. Tan joins Sinobiopharma ... as a China-based Unit Marketing Director for Organon, ... Organon, Ms. Tan held senior marketing management roles ...
... 8 Biopharmaceutical company Kiadis,Pharma reported preliminary ... mismatched bone marrow transplantations. Data was presented ... Roy during the prestigious,Presidential Symposium at the ... Goteborg, Sweden, on Monday, March 30, 2009. ...
... Inc. announced today that it has entered into ... NYSE: SNY ), providing the global ... platform for the research, development and commercialization of ... (ADCC). "We are extremely pleased about our partnership ...
Cached Biology Technology:Sinobiopharma, Inc. Appoints New Director of Marketing 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis 2
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
(Date:7/23/2014)... the International Journal of Fuzzy Systems ( ... Systems Association (TFSA). The cooperation will allow the journal ... fuzzy research., The International Journal of Fuzzy Systems ... with the theory, design and application of fuzzy systems, ... ranging from hardware to software. Launched in 1999, the ...
(Date:7/23/2014)... is available in German . ... modalities for orientation, some of which might be very ... the polarization pattern produced by sunlight in the atmosphere ... Max Planck Institute for Ornithology in Seewiesen, Germany, and ... that a night active mammal, the greater mouse-eared bat, ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2
... Sobrado, assistant professor of biochemistry at Virginia Tech, ... Prize, administered by the Ministry of Science and ... research is "a significant contribution to the diagnosis ... to a release distributed my MICIT. Sobrado, ...
... may have just provided the medical community a new way ... blocks of life forms and functions. University of Central ... program to analyze RNA motifs the subunits that make ... three building blocks of life along with DNA and proteins. ...
... in mice suggests a novel strategy for treating damaged ... approach potentially could improve cardiac function, minimize scar size, ... and avoid the risk of tissue rejection. In ... ONE , ( http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030329 ) the researchers isolated and ...
Cached Biology News:Contributions to diagnosis, treatment of tropical diseases recognized 2Stem cell study in mice offers hope for treating heart attack patients 2Stem cell study in mice offers hope for treating heart attack patients 3
...
... is used as an internal standard for ... dilution mass spectrometry. 5-OxoETE is a polyunsaturated ... 5-HETE in human neutrophils. It stimulates cytosolic ... of 2 nM. 5-OxoETE selectively stimulates the ...
... Scalable SNPstream System Delivers 4,600 to ... GenomeLab SNPstream Genotyping System is capable of ... per day. Part of the GenomeLab family ... can process up to 48 SNPs in ...
... are a mixture of Strep•Tag® II fusion ... The markers provide precise size references for ... Coomassie blue. Because each of the proteins ... can also be detected by the Strep•Tag ...
Biology Products: